New Trial Data Show EpiCor Postbiotic Alters Immune Biomarkers Within Hours of Ingestion

A single 500-mg dose of the yeast-derived postbiotic EpiCor produced measurable changes in immune-related biomarkers within 1 to 3 hours, according to a randomized, double-blind, placebo-controlled crossover trial published in Frontiers in Nutrition.^1,2

The study, conducted by NIS Labs in collaboration with Cargill, is among the first to characterize the acute biological response to a single postbiotic dose rather than relying solely on longer-term clinical outcomes.

For finished-product manufacturers building immune-health claims around postbiotics, the timing matters. Most prior human research on EpiCor has documented benefits after weeks of continuous use, such as reduced nasal congestion associated with allergic rhinitis.³ This trial instead asks what happens in the body before that longer-term effect could plausibly emerge.

"Multiple clinical trials have previously shown that long-term consumption of EpiCor supports immune health," said Gitte Jensen, PhD, director of NIS Labs and the study's lead investigator. "What excites us is seeing responses at 1, 2 and 3 hours, suggesting a coordinated biological response to a single dose compared with placebo. These early mechanistic responses after a single dose may contribute to the longer-term immune-supportive effects reported for this postbiotic."

What Did the Trial Measure?

Thirty healthy adults, ages 18 to 60, completed the crossover design, consuming either EpiCor or placebo on separate clinic visits with blood drawn at baseline and at 1, 2, and 3-hours post-consumption. Researchers tracked a panel of cytokines, chemokines, and growth factors alongside immune cell activation markers.

Compared with placebo, EpiCor was associated with reduced levels of several inflammation-related cytokines, including interferon-gamma and interleukin-1 receptor antagonist within the first hour, and interleukin-4, interleukin-7, and interleukin-8 by 2 hours. Researchers also observed shifts in the distribution of certain immune cell subsets across the sampling window.

The changes were selective rather than uniform: the majority of biomarkers tested showed no significant difference between groups, which the study authors describe as evidence of targeted modulation rather than broad immune suppression.

What Gap in the Science Does This Trial Address?

Postbiotics remain a comparatively new category within nutrition science, and the mechanisms by which specific formulations interact with the immune system are still being mapped. "Human research exploring what happens during the first few hours after consuming a postbiotic remains limited," said Justin Green, PhD, scientific affairs director for EpiCor at Cargill. "This study helps fill that gap by identifying early biological responses associated with consumption of EpiCor, adding to our understanding of how interactions in the gut may influence immune responses and reinforcing why ingredient-specific research matters."

EpiCor has accumulated more than a decade and a half of published research, including earlier acute-response work showing similar early cytokine shifts.⁴ The current trial expands that earlier dataset with a broader biomarker panel and an extended 3-hour observation window.

What Are the Study's Limitations and Next Steps?

The trial was conducted exclusively in healthy adults over a short observation period, and outcomes were limited to circulating biomarkers rather than functional or clinical measures of immune performance or gut health.

The authors call for further research using live-cell imaging to visualize immune cell trafficking directly, along with studies testing whether the same acute response pattern holds in populations facing an active immune challenge. Whether these early biomarker shifts translate into the clinically observed benefits reported in prior EpiCor research remains an open question for future trials to address.

References

1. Cargill. EpiCor postbiotic produces immune-related biomarker changes within hours. August 13, 2026. Accessed August 17, 2026. https://www.cargill.com/2026/epicor-postbiotic-produces-immune-related-biomarker-changes

2. Jensen GS, Cruickshank DD, Grinage EAF, et al. A yeast-derived postbiotic fermentate rapidly modulates inflammatory cytokines and immune surveillance markers in healthy adults: a randomized double-blind placebo-controlled cross-over trial. Front Nutr. 2026;13:1897550. doi:10.3389/fnut.2026.1897550

3. Moyad MA, Robinson LE, Kittelsrud JM, et al. Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Adv Ther. 2009;26:795-804. doi:10.1007/s12325-009-0057-y

4. Jensen GS, Redman KA, Benson KF, et al. Antioxidant bioavailability and rapid immune-modulating effects after consumption of a single acute dose of a high-metabolite yeast immunogen: results of a placebo-controlled double-blinded crossover pilot study. J Med Food. 2011;14:1002-1010. doi:10.1089/jmf.2010.0174